Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2018Developmental Medicine & Child NeurologyOpen Access

Mycophenolate mofetil in paediatric autoimmune or immune‐mediated diseases of the central nervous system: clinical experience and recommendations

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMargherita NosadiniUniversity of PaduaJGJonathan GadianMLMing LimUtah Department of Health

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nosadini et al. (2018) studied this question.

synapsesocial.com/papers/6ab471fa19c9d97504b8a94bhttps://doi.org/10.1111/dmcn.14020
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease2014 · 349 citations
  2. 2Investigations on CXCL13 in Anti– N -Methyl- D -Aspartate Receptor Encephalitis2014 · 184 citations
  3. 3Interobserver agreement for the assessment of handicap in stroke patients.1988 · 6,589 citations
  4. 4Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil2010 · 52 citations